Representative Court Decisions

  • Medical Diagnostics Labs. LLC v. Protagonist Therapeutics, Inc., 298 F. Supp. 3d 1241 (N.D. Cal. 2018) (participated in victory dismissing plaintiff’s case based upon the statutory safe harbor from patent infringement). 
  • Supernus Pharms. Inc. v. Actavis Inc., 2016 U.S. Dist. LEXIS 14111 (D.N.J. Feb. 5, 2016) (wherein Jason took the winning trial cross-examination of defendant’s obviousness expert in a case regarding Oxtellar XR® as well as the successful direct examination of one of Supernus’s expert – the patent was found non-obvious and that issue was not appealed).
  • Coalition For Affordable Drugs II LLC v. Cosmo Technologies Ltd., 2016 Pat. App. Lexis 13255 (Bd. Pat. App. & Interferences Oct. 5, 2016) (wherein Jason’s examination of the Petitioner’s expert was quoted by the Board against Petitioner when upholding the validity of the patent regarding Lialda®). 
  • The Medicines Co. v. Mylan Inc., 72 F. Supp. 3d 837 (N.D. Ill. 2014) (wherein Jason took the winning trial cross-examination of defendant’s obviousness expert in a case regarding Angiomax® – the patent was found non-obvious and that issue was not appealed). 
  • Glaxo Wellcome, Inc. v. Pharmadyne Corp., 32 F. Supp. 2d 265 (D. Md. 1998) (wherein Jason crafted the winning trial cross-examination of defendant’s obviousness expert in a case regarding Zantac®; the cross revealed the expert’s “monstrous error” of chemistry – the patent was found non-obvious and there was no appeal). 
  • Shire Dev. LLC. v. Mylan Pharmaceuticals, Inc., 2015 WL 1345322 (M.D. Fla. Mar. 23, 2015) (wherein Jason successfully argued the Markman hearing regarding claim construction of U.S. Patent 6,773,720 before trial in a case regarding Lialda®). 
  • Shire Dev. LLC. v. Mylan Pharmaceuticals, Inc., 235 F. Supp. 3d 1298 (M.D. Fla. Jan. 27, 2017) (wherein Jason took the then-winning direct examination of Shire’s main expert at trial in a case regarding Lialda®; and Mylan’s main expert was withdrawn at trial before Jason’s cross-examination – the case was reconsidered by the Court after an adverse Federal Circuit claim construction ruling in a related case).
  • Shire Dev. LLC v. Watson Pharmaceuticals, Inc., 932 F. Supp. 2d 1349 (S.D. Fla. 2013) (wherein Jason successfully briefed Shire’s opposition to summary judgment of non-infringement regarding a generic version of Lialda®).
  • Shire Dev. LLC v. Watson Pharmaceuticals, Inc., 2013 WL 1912208 (S.D. Fla. May 9, 2013) (wherein Jason took the winning direct trial examination of Shire’s expert on melting point and the winning trial cross-examination of Watson’s expert on that same issue; the ruling in Shire’s favor regarding melting point was never appealed – the victory was reversed on appeal on other grounds and remanded).
  • Shire Dev. LLC v. Watson Pharms., Inc., 2016 U.S. Dist. LEXIS 40360, 2016 WL 1258885 (S.D. Fla. 2016) (a second trial victory regarding Lialda®, wherein Jason took the winning direct trial examination of Shire’s main expert and the winning cross-examination of Watson’s main expert – ultimately reversed on appeal on claim construction).
  • Shire LLC v. Sandoz Inc., 2012 U.S. Dist. LEXIS 161964, 2012 WL 5494944 (D. Col. 2012) (wherein Jason participated in the successful Markman briefing and hearing in a case regarding Intuniv®).
  • Shire LLC v. Teva Pharmaceuticals USA Inc., 2012 WL 12974072 (D. Del. Aug. 1, 2012) (wherein Jason briefed the successful opposition to a Daubert motion against Shire’s expert regarding Intuniv®).
  • Glaxo Wellcome, Inc. v. Andrx Pharmaceuticals, Inc., 344 F.3d 1226 (Fed. Cir. 2003) (wherein Jason participated in the successful appellate briefing, on behalf of plaintiff Glaxo in a case regarding Wellbutrin SR®, resulting in a reversal of summary judgment of non-infringement).
  • Andrx Pharmaceuticals, LLC v. GlaxoSmithKline, PLC, 236 F.R.D. 583 (S.D. Fla. 2006), aff’d., 2006 WL 2403942 (S.D. Fla. 2006) (wherein Jason successfully briefed and argued motions on behalf of Glaxo, resulting in opposing counsel being denied access to confidential information in a case regarding Wellbutrin XL®).
  • Eyal R.D. Corp. v. Jewelex New York Ltd., 784 F. Supp. 2d 441 (S.D.N.Y. 2011) (wherein Jason successfully briefed and argued federal copyright law preemption of state law claims in a case involving jewelry design).
  • Concat LP v. Unilever, PLC, 350 F. Supp. 2d 796 (N.D. Cal. 2004) (wherein Jason participated in the successful briefing that sent the case to arbitration).
  • University of Minnesota v. Glaxo Wellcome, Inc., 58 F. Supp. 2d 1036 (D. Minn. 1999) and 44 F.Supp.2d 998 (D. Minn. 1999) (wherein Jason crafted the winning arguments on behalf of Glaxo that maintained the case in Federal Court over supposed Eleventh Amendment objections; the case involved a licensing dispute over the AIDS drug Ziagen®).
  • Glaxo Group Ltd. v. Apotex, Inc., 130 F. Supp. 2d 1006 (N.D. Ill. 2001) (wherein Jason participated in crafting the winning arguments on behalf of Glaxo that maintained a novel declaratory judgment action for future infringement in Federal Court for a non-Hatch-Waxman antibiotic Ceftin®).
  • Glaxo Wellcome, Inc. v. Ben Venue Labs., 1998 WL 965993 (N.D. Ohio Jul. 31, 1998) (wherein Jason crafted the winning cross-examination of the opposing expert that overcame non-infringement and obviousness arguments in a case regarding Zantac®).
  • Pfizer, Inc. v. Perrigo Co., 988 F. Supp. 686 (S.D.N.Y. 1997) (wherein Jason, on behalf of Pfizer, crafted the successful cross-examination of the opposing chemistry expert in a case involving Plax® oral rinse).